Comparing the evidence for botulinum neurotoxin injections in paediatric anterior drooling: a scoping review
Open Access
- 4 November 2023
- journal article
- review article
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 183 (1) , 83-93
Abstract
Paediatric anterior drooling has a major impact on the daily lives of children and caregivers. Intraglandular botulinum neurotoxin type-A (BoNT-A) injections are considered an effective treatment to diminish drooling. However, there is no international consensus on which major salivary glands should be injected to obtain optimal treatment effect while minimizing the risk of side effects. This scoping review aimed to explore the evidence for submandibular BoNT-A injections and concurrent submandibular and parotid (i.e. four-gland) injections, respectively, and assess whether outcomes could be compared across studies to improve decision making regarding the optimal initial BoNT-A treatment approach for paediatric anterior drooling. PubMed, Embase, and Web of Science were searched to identify relevant studies (until October 1, 2023) on submandibular or four-gland BoNT-A injections for the treatment of anterior drooling in children with neurodevelopmental disabilities. Similarities and differences in treatment, patient, outcome, and follow-up characteristics were assessed. Twenty-eight papers were identified; 7 reporting on submandibular injections and 21 on four-gland injections. No major differences in treatment procedures or timing of follow-up were found. However, patient characteristics were poorly reported, there was great variety in outcome measurement, and the assessment of side effects was not clearly described. Conclusion: This review highlights heterogeneity in outcome measures and patient population descriptors among studies on paediatric BoNT-A injections, limiting the ability to compare treatment effectiveness between submandibular and four-gland injections. These findings emphasize the need for more extensive and uniform reporting of patient characteristics and the implementation of a core outcome measurement set to allow for comparison of results between studies and facilitate the optimization of clinical practice guidelines. What is Known:• There is no international consensus on which salivary glands to initially inject with BoNT-A to treat paediatric drooling. What is New:• Concluding on the optimal initial BoNT-A treatment based on literature is currently infeasible. There is considerable heterogeneity in outcome measures used to quantify anterior drooling.and clinical characteristics of children treated with intraglandular BoNT-A are generally insufficiently reported.• Consensus-based sets of outcome measures and patient characteristics should be developed and implemented.Keywords
This publication has 81 references indexed in Scilit:
- Secondary Effects of Botulinum Toxin Injections Into Salivary Glands for the Management of Pediatric DroolingJournal of Craniofacial Surgery, 2013
- Methods in Comparative Effectiveness ResearchJournal of Clinical Oncology, 2012
- Use of botulinum neurotoxin A in uncontrolled salivation in children with cerebral palsy: a pilot studyInternational Journal of Oral and Maxillofacial Surgery, 2012
- Developing core outcome sets for clinical trials: issues to considerTrials, 2012
- Investigating clinical heterogeneity in systematic reviews: a methodologic review of guidance in the literatureBMC Medical Research Methodology, 2012
- Effect of Botulinum Toxin A Injection into the Salivary Glands for Sialorrhea in Children with Neurologic DisordersAnnals of Rehabilitation Medicine, 2012
- Clinical practiceEuropean Journal of Pediatrics, 2011
- Does Motor Performance Matter in Botulinum Toxin Efficacy for Drooling?Pediatric Neurology, 2011
- Botox® to reduce drooling in a paediatric population with neurological impairments: a Phase I studyInternational Journal of Language & Communication Disorders, 2011
- Scoping studies: advancing the methodologyImplementation Science, 2010